BACKGROUND: Children with positive islet autoantibodies monitored prospectively avoid metabolic decompensation at type 1 diabetes (T1D) diagnosis. However, the effects of early diagnosis and treatment on preservation of insulin secretion and long-term metabolic control are unknown. We compared characteristics of children detected through research screening (Diabetes Autoimmunity Study in the Young [DAISY]) versus community controls at baseline and, in a subset, 6- and 12-month metabolic outcomes. MATERIALS AND METHODS: This was a case-control study comparing DAISY children with T1D to children diagnosed in the general community. All participants underwent mixed-meal tolerance testing; a subset wore a continuous glucose monitoring (CGM) device. Fasting and stimulated C-peptide levels, insulin dose-adjusted hemoglobin A1c (IDAA1c), and CGM variables were compared. RESULTS: Children (21 DAISY, 21 community) were enrolled and matched by age, time of diagnosis, and diabetes duration; 18 were enrolled within 2 months and 24 within 2.5 years on average from diagnosis. In the overall group and the subgroup of participants enrolled 2.5 years from diagnosis, there were no IDAA1c or C-peptide differences between DAISY versus community children. The subgroup of DAISY versus community children enrolled near diagnosis, however, had lower baseline hemoglobin A1c (6.5±1.4% vs. 9.2±2.9%; P=0.0007) and IDAA1c (7.4±2.1% vs. 11.2±3.5%; P=0.04) and higher stimulated C-peptide (2.5±0.5 vs. 1.6±0.2 ng/mL; P=0.02). In this subgroup, IDAA1c differences persisted at 6 months but not at 1 year. CGM analyses revealed lower minimum overnight glycemia in community children (72 vs. 119 mg/dL; P=0.01). CONCLUSIONS: Favorable patterns of IDAA1c and C-peptide seen in research-screened versus community-diagnosed children with T1D within 2 months of diagnosis are no longer apparent 1 year from diagnosis.
BACKGROUND:Children with positive islet autoantibodies monitored prospectively avoid metabolic decompensation at type 1 diabetes (T1D) diagnosis. However, the effects of early diagnosis and treatment on preservation of insulin secretion and long-term metabolic control are unknown. We compared characteristics of children detected through research screening (Diabetes Autoimmunity Study in the Young [DAISY]) versus community controls at baseline and, in a subset, 6- and 12-month metabolic outcomes. MATERIALS AND METHODS: This was a case-control study comparing DAISY children with T1D to children diagnosed in the general community. All participants underwent mixed-meal tolerance testing; a subset wore a continuous glucose monitoring (CGM) device. Fasting and stimulated C-peptide levels, insulin dose-adjusted hemoglobin A1c (IDAA1c), and CGM variables were compared. RESULTS:Children (21 DAISY, 21 community) were enrolled and matched by age, time of diagnosis, and diabetes duration; 18 were enrolled within 2 months and 24 within 2.5 years on average from diagnosis. In the overall group and the subgroup of participants enrolled 2.5 years from diagnosis, there were no IDAA1c or C-peptide differences between DAISY versus community children. The subgroup of DAISY versus community children enrolled near diagnosis, however, had lower baseline hemoglobin A1c (6.5±1.4% vs. 9.2±2.9%; P=0.0007) and IDAA1c (7.4±2.1% vs. 11.2±3.5%; P=0.04) and higher stimulated C-peptide (2.5±0.5 vs. 1.6±0.2 ng/mL; P=0.02). In this subgroup, IDAA1c differences persisted at 6 months but not at 1 year. CGM analyses revealed lower minimum overnight glycemia in community children (72 vs. 119 mg/dL; P=0.01). CONCLUSIONS: Favorable patterns of IDAA1c and C-peptide seen in research-screened versus community-diagnosed children with T1D within 2 months of diagnosis are no longer apparent 1 year from diagnosis.
Authors: Kevan C Herold; William Hagopian; Julie A Auger; Ena Poumian-Ruiz; Lesley Taylor; David Donaldson; Stephen E Gitelman; David M Harlan; Danlin Xu; Robert A Zivin; Jeffrey A Bluestone Journal: N Engl J Med Date: 2002-05-30 Impact factor: 91.245
Authors: C Törn; M Landin-Olsson; A Lernmark; J P Palmer; H J Arnqvist; G Blohmé; F Lithner; B Littorin; L Nyström; B Scherstén; G Sundkvist; L Wibell; J Ostman Journal: J Clin Endocrinol Metab Date: 2000-12 Impact factor: 5.958
Authors: Jennifer M Barker; Katherine J Barriga; Liping Yu; Dongmei Miao; Henry A Erlich; Jill M Norris; George S Eisenbarth; Marian Rewers Journal: J Clin Endocrinol Metab Date: 2004-08 Impact factor: 5.958
Authors: Jerry P Palmer; G Alexander Fleming; Carla J Greenbaum; Kevan C Herold; Lisa D Jansa; Hubert Kolb; John M Lachin; Kenneth S Polonsky; Paolo Pozzilli; Jay S Skyler; Michael W Steffes Journal: Diabetes Date: 2004-01 Impact factor: 9.461
Authors: Jennifer M Barker; Stephanie H Goehrig; Katherine Barriga; Michelle Hoffman; Robert Slover; George S Eisenbarth; Jill M Norris; Georgeanna J Klingensmith; Marian Rewers Journal: Diabetes Care Date: 2004-06 Impact factor: 19.112
Authors: Heba M Ismail; Carmella Evans-Molina; Linda A DiMeglio; Dorothy J Becker; Ingrid Libman; Emily K Sims; David Boulware; Kevan C Herold; Lisa Rafkin; Jay Skyler; Mario A Cleves; Jerry Palmer; Jay M Sosenko Journal: Pediatr Diabetes Date: 2019-04-15 Impact factor: 4.866
Authors: Andrea K Steck; Helena Elding Larsson; Xiang Liu; Riitta Veijola; Jorma Toppari; William A Hagopian; Michael J Haller; Simi Ahmed; Beena Akolkar; Åke Lernmark; Marian J Rewers; Jeffrey P Krischer Journal: Pediatr Diabetes Date: 2017-01-27 Impact factor: 3.409
Authors: Anette-G Ziegler; Ezio Bonifacio; Alvin C Powers; John A Todd; Leonard C Harrison; Mark A Atkinson Journal: Diabetes Date: 2016-11 Impact factor: 9.461